Concord Biotech Ltd. (IN:CONCORDBIO)
:CONCORDBIO
Want to see IN:CONCORDBIO full AI Analyst Report?
CONCORDBIO Stock Chart & Stats
₹1338.60
₹62.10(2.74%)
At close: 4:00 PM EST
₹1338.60
₹62.10(2.74%)
Day’s Range― - ―
52-Week Range₹987.05 - ₹2,149.90
Previous CloseN/A
Volume295.44K
Average Volume (3M)12.81K
Market Cap
₹116.70B
Enterprise Value₹116.59B
Total Cash (Recent Filing)₹3.81B
Total Debt (Recent Filing)₹16.07M
Price to Earnings (P/E)54.6
Beta1.02
Next Earnings
May 21, 2026EPS Estimate
8.9Next Dividend Ex-DateN/A
Dividend Yield0.8%
Share Statistics
EPS (TTM)30.92
Shares Outstanding104,616,200
10 Day Avg. Volume31,605
30 Day Avg. Volume12,808
Financial Highlights & Ratios
PEG Ratio2.27
Price to Book (P/B)9.60
Price to Sales (P/S)14.50
P/FCF Ratio127.69
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)37.79
Revenue Forecast (FY)₹14.24B
Bulls Say, Bears Say
Bulls Say
Strong Balance Sheet With Low LeverageA low debt-to-equity profile and high equity ratio provide durable financial flexibility, lowering refinancing and solvency risk. This supports multi-year investments in fermentation capacity, shields operations in downturns, and preserves optionality for strategic M&A or R&D funding.
Consistent Positive Operating Cash FlowSustained positive and growing operating cash flow underpins the company's ability to self-fund working capital, capex and process development for complex APIs. Reliable cash generation reduces reliance on external capital and enables steady reinvestment in manufacturing scale and quality systems.
Sustained Revenue Growth With Healthy MarginsConsistent revenue expansion and robust profitability reflect competitive positioning in fermentation-based APIs and effective cost control. Durable margins indicate pricing power and operational efficiency, supporting long-term reinvestment in R&D and scalable manufacturing capabilities.
Bears Say
Inconsistent Free Cash Flow GrowthFluctuating free cash flow growth undermines predictability of funds available for sustained capital projects, capacity expansion and shareholder returns. Variable FCF can constrain multi-year investment planning in large fermentation assets and increase reliance on timing of cash cycles.
Slight Gross Margin DeteriorationA declining gross margin suggests input cost, yield or mix pressures in complex API manufacturing. If persistent, margin erosion could compress profitability despite revenue growth, forcing margin-restoring actions like price increases, efficiency programs, or product mix shifts that take time to implement.
Recent EPS ContractionNegative EPS growth indicates near-term profit pressure relative to prior periods. If the trend continues it may reflect margin, cost or demand headwinds that reduce retained earnings and limit internal funding for R&D and capacity, slowing strategic initiatives until profitability rebounds.
Concord Biotech Ltd. News
CONCORDBIO FAQ
What was Concord Biotech Ltd.’s price range in the past 12 months?
Concord Biotech Ltd. lowest stock price was ₹987.05 and its highest was ₹2149.90 in the past 12 months.
What is Concord Biotech Ltd.’s market cap?
Concord Biotech Ltd.’s market cap is ₹116.70B.
When is Concord Biotech Ltd.’s upcoming earnings report date?
Concord Biotech Ltd.’s upcoming earnings report date is May 21, 2026 which is today.
How were Concord Biotech Ltd.’s earnings last quarter?
Concord Biotech Ltd. released its earnings results on Feb 11, 2026. The company reported ₹6.3 earnings per share for the quarter, missing the consensus estimate of ₹7.2 by -₹0.9.
Is Concord Biotech Ltd. overvalued?
According to Wall Street analysts Concord Biotech Ltd.’s price is currently Overvalued.
Does Concord Biotech Ltd. pay dividends?
Concord Biotech Ltd. pays a Notavailable dividend of ₹10.7 which represents an annual dividend yield of 0.8%. See more information on Concord Biotech Ltd. dividends here
What is Concord Biotech Ltd.’s EPS estimate?
Concord Biotech Ltd.’s EPS estimate is 8.9.
How many shares outstanding does Concord Biotech Ltd. have?
Concord Biotech Ltd. has 104,616,200 shares outstanding.
What happened to Concord Biotech Ltd.’s price movement after its last earnings report?
Concord Biotech Ltd. reported an EPS of ₹6.3 in its last earnings report, missing expectations of ₹7.2. Following the earnings report the stock price went down -3.042%.
Which hedge fund is a major shareholder of Concord Biotech Ltd.?
Currently, no hedge funds are holding shares in IN:CONCORDBIO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Concord Biotech Ltd.
Concord Biotech Limited, a biopharma company, engages in the research and development, manufacturing, marketing, and sale of pharmaceutical products in India and internationally. It provides fermentation based active pharmaceutical ingredients in immunosuppressants, anti-bacterial, oncology, antifungal, and other therapeutic areas. The company also offers tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus, and pimecrolimus for immunosuppressants therapeutic segment; temsirolimus, everolimus, romidepsin, mitomycin, midostaurin, and dactinomycin for oncology therapeutic segment; mupirocin, mupirocin calcium, vancomycin hydrochloride, and teicoplanin for anti-bacterial applications; anidulafungin, caspofungi, and micafungin sodium for anti-fungal therapeutic segment; and lovastatin and pravastatin sodium for other applications. In addition, it provides contract research and manufacturing services in the areas of fermentation and semi-synthesis products. Concord Biotech Limited was incorporated in 1984 and is based in Ahmedabad, India.
Technical Analysis
Biocon Limited
―
Blue Jet Healthcare Limited
―
Jubilant Ingrevia Ltd.
―
Piramal Pharma Limited
―
Syngene International Ltd.
―